Treatment of idiopathic pulmonary hemosiderosis in children: a systematic review
Rituximab shows potential as a steroid-sparing treatment for a rare but devastating childhood lung bleeding disease, though relapse rates highlight enormous remaining need.
Idiopathic pulmonary hemosiderosis (IPH) is a rare potentially fatal pediatric disease characterized by diffuse alveolar hemorrhage; this PROSPERO-registered systematic review synthesizes treatment evidence from 149 studies including 494 children. Corticosteroids remain the only widely used first-line therapy, with rituximab showing promise as a steroid-sparing agent, but high relapse rates and 27% mortality in some cohorts underscore the extreme unmet therapeutic need.
What the study was
- Study design
- Systematic review (PROSPERO registered)
- Category
- T9: Rare diseases with high unmet need
- Maturity
- Validated
- Journal
- Frontiers in Pediatrics
Why it surfaced
IPH is a rare pediatric disease with high mortality and no approved therapy; this first comprehensive systematic review quantifies the treatment landscape and rituximab signal actionable for pipeline prioritization in rare disease contexts.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.